| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3199698 | Journal of Allergy and Clinical Immunology | 2011 | 13 Pages |
Abstract
The results of this study indicate that omalizumab is an effective treatment option for patients with CU with IgE autoantibodies against TPO who are refractory to conventional treatment.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Marcus MD, Sabine MD, Thomas MD, Tilo MD, Matthias PhD, Stefan PhD, Randolf MD, Jürgen MD, Nicolas MD, Thilo MD, Andreas MD, Jörg MD, Martin MD, Michael MD, Kristian MD, Franziska MD, Knut MD, Kaushik BDS, MScD, Petra MD,